{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:11:53Z","timestamp":1792685513659,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32022015"],"award-info":[{"award-number":["32022015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91857000"],"award-info":[{"award-number":["91857000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32401274"],"award-info":[{"award-number":["32401274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["CIFMS-2021-I2M-5-015"],"award-info":[{"award-number":["CIFMS-2021-I2M-5-015"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20230786"],"award-info":[{"award-number":["BK20230786"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114973","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:04:28Z","timestamp":1777964668000},"page":"114973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vivo genetic circuit drives systemic PARP1 siRNA assembly into small extracellular vesicles for BRCA2-deficient breast cancer therapy"],"prefix":"10.1016","volume":"395","author":[{"given":"Ayesha","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzair","family":"Ur-Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronglu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114973_bb0010","author":"WHO"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2026.114973_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114973_bb0025","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/annonc\/mdh218","article-title":"Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer","volume":"15","author":"Alexopoulos","year":"2004","journal-title":"Ann. Oncol."},{"issue":"6559","key":"10.1016\/j.jconrel.2026.114973_bb0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ng0596-120","article-title":"Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families","volume":"13","author":"Phelan","year":"1996","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114973_bb0040","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1471-4914(02)02434-6","article-title":"The relationship between the roles of BRCA genes in DNA repair and cancer predisposition","volume":"8","author":"Tutt","year":"2002","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114973_bb0050","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/0008-5472.CAN-24-2531","article-title":"Harnessing STING signaling and natural killer cells overcomes PARP inhibitor resistance in homologous recombination-deficient breast cancer","volume":"85","author":"Pedretti","year":"2025","journal-title":"Cancer Res."},{"issue":"7035","key":"10.1016\/j.jconrel.2026.114973_bb0055","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.jconrel.2026.114973_bb0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114973_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"362","key":"10.1016\/j.jconrel.2026.114973_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114973_bb0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrm2851","article-title":"Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis","volume":"11","author":"Moynahan","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114973_bb0080","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114973_bb0085","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114973_bb0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.jconrel.2026.114973_bb0095","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114973_bb0100","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114973_bb0105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1600-6143.2004.00530.x","article-title":"RNA interference: a potent tool for gene-specific therapeutics","volume":"4","author":"Ichim","year":"2004","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jconrel.2026.114973_bb0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA interference (RNAi)-based therapeutics: delivering on the promise?","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114973_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","article-title":"Current prospects for RNA interference-based therapies","volume":"12","author":"Davidson","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114973_bb0120","first-page":"187","article-title":"Therapeutic siRNA: principles, challenges, and strategies","volume":"85","author":"Gavrilov","year":"2012","journal-title":"Yale J. Biol. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114973_bb0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nbt.1830","article-title":"SiRNA delivery with exosome nanoparticles","volume":"29","author":"van den Boorn","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114973_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40291-018-0338-8","article-title":"Current transport systems and clinical applications for small interfering RNA (siRNA) drugs","volume":"22","author":"Liu","year":"2018","journal-title":"Mol. Diagn. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114973_bb0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.114973_bb0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2017.02.020","article-title":"Exosomes: therapy delivery tools and biomarkers of diseases","volume":"174","author":"Barile","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114973_bb0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41422-021-00491-z","article-title":"In vivo self-assembled small RNAs as a new generation of RNAi therapeutics","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res."},{"issue":"49","key":"10.1016\/j.jconrel.2026.114973_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201903637","article-title":"Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery","volume":"31","author":"Kim","year":"2019","journal-title":"Adv. Mater."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114973_bb0155","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1093\/nar\/gkac456","article-title":"Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics","volume":"50","author":"Humphreys","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0160","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1038\/s41467-022-33436-0","article-title":"In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114973_bb0165","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1089\/10430349950017734","article-title":"High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA","volume":"10","author":"Zhang","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114973_bb0170","first-page":"3","article-title":"The mechanism of naked DNA uptake and expression","volume":"54","author":"Wolff","year":"2005","journal-title":"Adv. Genet."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114973_bb0175","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: from biomarkers to mediators of physiology and disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gpb.2015.02.001","article-title":"Exosome and exosomal microRNA: trafficking, sorting, and function","volume":"13","author":"Zhang","year":"2015","journal-title":"Genom. Proteom. Bioinforma."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114973_bb0185","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1093\/nar\/gkr254","article-title":"Characterization of extracellular circulating microRNA","volume":"39","author":"Turchinovich","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"39","key":"10.1016\/j.jconrel.2026.114973_bb0190","doi-asserted-by":"crossref","first-page":"24213","DOI":"10.1073\/pnas.2008323117","article-title":"Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides","volume":"117","author":"Geekiyanage","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114973_bb0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1017\/S0016672300018061","article-title":"Cell numbers and cell sizes in organs of mice selected for large and small body size","volume":"31","author":"Falconer","year":"1978","journal-title":"Genet. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114973_bb0200","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4161\/cc.8.3.7608","article-title":"Does the cell number 10(9) still really fit one gram of tumor tissue?","volume":"8","author":"Del Monte","year":"2009","journal-title":"Cell Cycle"},{"issue":"6330","key":"10.1016\/j.jconrel.2026.114973_bb0205","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114973_bb0210","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114973_bb0215","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14737140.2024.2357822","article-title":"Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis","volume":"24","author":"Dai","year":"2024","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114973_bb0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann. Oncol."},{"issue":"8060","key":"10.1016\/j.jconrel.2026.114973_bb0225","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41586-025-08749-x","article-title":"BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments","volume":"640","author":"Lahiri","year":"2025","journal-title":"Nature"},{"issue":"179","key":"10.1016\/j.jconrel.2026.114973_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005568","article-title":"Cell-based therapeutics: the next pillar of medicine","volume":"5","author":"Fischbach","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114973_bb0235","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: a potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114973_bb0240","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41573-021-00285-3","article-title":"Engineering living therapeutics with synthetic biology","volume":"20","author":"Cubillos-Ruiz","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114973_bb0245","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114973_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/polym14132601","article-title":"Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect","volume":"14","author":"Ejigah","year":"2022","journal-title":"Polymers (Basel)"},{"issue":"7","key":"10.1016\/j.jconrel.2026.114973_bb0255","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"15","key":"10.1016\/j.jconrel.2026.114973_bb0260","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","volume":"81","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"issue":"7716","key":"10.1016\/j.jconrel.2026.114973_bb0265","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114973_bb0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cmet.2011.03.004","article-title":"PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation","volume":"13","author":"Bai","year":"2011","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114973_bb0275","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/hep.26763","article-title":"Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis","volume":"59","author":"Mukhopadhyay","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114973_bb0280","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"7893","key":"10.1016\/j.jconrel.2026.114973_bb0285","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41586-021-04234-3","article-title":"MicroRNA sequence codes for small extracellular vesicle release and cellular retention","volume":"601","author":"Garcia-Martin","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114973_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cells9041044","article-title":"Sorting mechanisms for MicroRNAs into extracellular vesicles and their associated diseases","volume":"9","author":"Groot","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0295","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2019.09.014","article-title":"Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1","volume":"72","author":"Jiang","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/ATVBAHA.117.309795","article-title":"Extracellular vesicles secreted by atherogenic macrophages transfer MicroRNA to inhibit cell migration","volume":"38","author":"Nguyen","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114973_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-013-1084-8","article-title":"Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies","volume":"113","author":"Akers","year":"2013","journal-title":"J. Neuro-Oncol."},{"issue":"6478","key":"10.1016\/j.jconrel.2026.114973_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:50:47Z","timestamp":1783137047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":62,"alternative-id":["S0168365926003767"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114973","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo genetic circuit drives systemic PARP1 siRNA assembly into small extracellular vesicles for BRCA2-deficient breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114973"}}